Managed Healthcare Executive1d
The Future of Gene Therapies and Their Impact on Payers | AMCP Annual 2025
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
Fierce Pharma1d
UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
CRISPR gene editing breakthrough eliminates 50% of head, neck tumors
Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...
Fierce Biotech1d
Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
BioPharma Dive4d
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Managed Healthcare Executive1d
Gene Therapies for Rare Diseases Twice as Likely to Win FDA Nod, Study Finds
None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.
Fierce Biotech2d
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
Fierce Pharma2d
Gene therapy CDMO Artis BioSolutions launches with acquisition of Landmark Bio
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...